Ninety One UK Ltd Acquires 61,655 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Ninety One UK Ltd grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 12.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 569,045 shares of the medical research company's stock after purchasing an additional 61,655 shares during the quarter. Ninety One UK Ltd owned approximately 0.15% of Thermo Fisher Scientific worth $283,157,000 as of its most recent SEC filing.

Several other institutional investors have also recently modified their holdings of TMO. Revolve Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after buying an additional 20 shares during the period. One Charles Private Wealth Services LLC boosted its stake in Thermo Fisher Scientific by 4.2% in the 4th quarter. One Charles Private Wealth Services LLC now owns 499 shares of the medical research company's stock worth $260,000 after purchasing an additional 20 shares during the period. Holderness Investments Co. boosted its stake in Thermo Fisher Scientific by 1.7% in the 4th quarter. Holderness Investments Co. now owns 1,277 shares of the medical research company's stock worth $664,000 after purchasing an additional 21 shares during the period. Port Capital LLC boosted its stake in shares of Thermo Fisher Scientific by 1.6% during the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock worth $721,000 after buying an additional 22 shares during the last quarter. Finally, Clark Capital Management Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after buying an additional 23 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Monday, April 28th. The shares were sold at an average price of $429.93, for a total value of $128,979.00. Following the transaction, the executive vice president owned 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $6.70 during midday trading on Wednesday, reaching $419.47. 2,735,091 shares of the stock were exchanged, compared to its average volume of 1,987,159. The company's fifty day moving average is $409.11 and its 200-day moving average is $478.29. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The firm has a market cap of $158.35 billion, a PE ratio of 24.60, a PEG ratio of 2.27 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $385.46 and a 52 week high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping analysts' consensus estimates of $5.10 by $0.05. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. Thermo Fisher Scientific had a net margin of 15.19% and a return on equity of 17.15%. The firm's revenue was up .2% compared to the same quarter last year. During the same quarter last year, the company earned $5.11 EPS. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.41%. The ex-dividend date of this dividend is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Analyst Ratings Changes

A number of equities analysts have recently commented on TMO shares. UBS Group downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "neutral" rating and reduced their price objective for the stock from $500.00 to $460.00 in a research note on Tuesday. Robert W. Baird dropped their target price on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a report on Thursday, April 24th. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Wednesday, May 21st. Barclays lowered their price target on shares of Thermo Fisher Scientific from $475.00 to $450.00 and set an "equal weight" rating on the stock in a report on Tuesday, June 24th. Finally, Royal Bank Of Canada cut their target price on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research report on Thursday, April 24th. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $601.05.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.